1
|
Angeli A, Occhini A, Renzi G, Capperucci A, Ferraroni M, Tanini D, Supuran CT. Thia- and Seleno-Michael Reactions for the Synthesis of Carbonic Anhydrases Inhibitors. ChemMedChem 2024:e202400345. [PMID: 39031732 DOI: 10.1002/cmdc.202400345] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2024] [Revised: 06/20/2024] [Accepted: 06/20/2024] [Indexed: 07/22/2024]
Abstract
Novel chalcogen-containing amides and esters bearing the benzenesulfonamide moiety have been synthesised upon nucleophilic conjugate addition of thiols and selenols to suitable electron-deficient alkenes. The activity of the synthesised compounds as Carbonic Anhydrases inhibitors has been investigated in vitro and the inhibition mechanism has been elucidated by X-rays studies.
Collapse
Affiliation(s)
- Andrea Angeli
- NEUROFARBA Deptartment, Sezione di Scienze Farmaceutiche, University of Florence, Via Ugo Schiff 6, Sesto Fiorentino, 50019, Florence, Italy
| | - Alessio Occhini
- Department of Chemistry "Ugo Schiff" (DICUS), University of Florence, Via della Lastruccia 3-13, Sesto Fiorentino, I-50019, Florence, Italy
| | - Gioele Renzi
- NEUROFARBA Deptartment, Sezione di Scienze Farmaceutiche, University of Florence, Via Ugo Schiff 6, Sesto Fiorentino, 50019, Florence, Italy
| | - Antonella Capperucci
- Department of Chemistry "Ugo Schiff" (DICUS), University of Florence, Via della Lastruccia 3-13, Sesto Fiorentino, I-50019, Florence, Italy
| | - Marta Ferraroni
- Department of Chemistry "Ugo Schiff" (DICUS), University of Florence, Via della Lastruccia 3-13, Sesto Fiorentino, I-50019, Florence, Italy
| | - Damiano Tanini
- Department of Chemistry "Ugo Schiff" (DICUS), University of Florence, Via della Lastruccia 3-13, Sesto Fiorentino, I-50019, Florence, Italy
| | - Claudiu T Supuran
- NEUROFARBA Deptartment, Sezione di Scienze Farmaceutiche, University of Florence, Via Ugo Schiff 6, Sesto Fiorentino, 50019, Florence, Italy
| |
Collapse
|
2
|
Huang X, Zhang Y, Zhang W, Qin C, Zhu Y, Fang Y, Wang Y, Tang C, Cao F. Osteopontin-Targeted and PPARδ-Agonist-Loaded Nanoparticles Efficiently Reduce Atherosclerosis in Apolipoprotein E -/- Mice. ACS OMEGA 2022; 7:28767-28778. [PMID: 36033674 PMCID: PMC9404512 DOI: 10.1021/acsomega.2c00575] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/28/2022] [Accepted: 08/02/2022] [Indexed: 06/15/2023]
Abstract
Atherosclerosis is the leading cause of vascular pathologies and acute cardiovascular events worldwide. Early theranostics of atherosclerotic plaque formation is critical for the prevention of associated cardiovascular complications. Osteopontin (OPN) expression in vascular smooth muscle cells (VSMCs) has been reported as a promising molecular target for the diagnosis and treatment of atherosclerotic plaques. The PPARδ agonist GW1516 has been shown to inhibit VSMC migration and apoptosis. However, GW1516 has low aqueous solubility and poor oral bioavailability, which are major obstacles to its broad development and application. In this study, GW1516@NP-OPN, which is anti-OPN-targeted and loaded with the PPARδ agonist GW1516, was synthesized using a nanoprecipitation method. The uptake of GW1516@NP-OPN was examined using fluorescence microscopy and flow cytometry assay in VSMC in vitro models. Using the Transwell assay and acridine orange/ethidium bromide staining methods, we observed that the inhibition of VSMCS migration and apoptosis was significantly higher in cells treated with GW1516@NP-OPN than those treated with free GW1516. The western blot assay further confirmed that GW1516@NP-OPN can increase FAK phosphorylation and TGF-βprotein expression. The effect of NPs was further tested in vivo. The atherosclerotic lesion areas were greatly decreased by GW1516@NP-OPN compared with the free drug treatment in apolipoprotein E-/- mice models. Consequently, our results showed that GW1516@NP-OPN stabilizes the PPARδ agonist aqueous formulation, improves its anti-plaque formation activities in vivo and in vitro, and can therefore be recommended for further development as a potential anti-atherosclerotic nanotherapy.
Collapse
Affiliation(s)
- Xu Huang
- Department
of Geriatric Cardiology, National Clinical Research Center for Geriatric
Diseases, 2nd Medical Center, Chinese PLA
General Hospital, Beijing 100853, China
- Department
of Cardiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu 210009, P.R. China
| | - Yang Zhang
- Department
of Geriatric Cardiology, National Clinical Research Center for Geriatric
Diseases, 2nd Medical Center, Chinese PLA
General Hospital, Beijing 100853, China
| | - Weiwei Zhang
- Nankai
University School of Medicine, Nankai University, Tianjin 300073, China
| | - Cheng Qin
- Department
of Geriatric Cardiology, National Clinical Research Center for Geriatric
Diseases, 2nd Medical Center, Chinese PLA
General Hospital, Beijing 100853, China
| | - Yan Zhu
- Nankai
University School of Medicine, Nankai University, Tianjin 300073, China
| | - Yan Fang
- Department
of Geriatric Cardiology, National Clinical Research Center for Geriatric
Diseases, 2nd Medical Center, Chinese PLA
General Hospital, Beijing 100853, China
| | - Yabin Wang
- Department
of Geriatric Cardiology, National Clinical Research Center for Geriatric
Diseases, 2nd Medical Center, Chinese PLA
General Hospital, Beijing 100853, China
| | - Chengchun Tang
- Department
of Cardiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu 210009, P.R. China
| | - Feng Cao
- Department
of Geriatric Cardiology, National Clinical Research Center for Geriatric
Diseases, 2nd Medical Center, Chinese PLA
General Hospital, Beijing 100853, China
| |
Collapse
|
3
|
Kadayat TM, Shrestha A, Jeon YH, An H, Kim J, Cho SJ, Chin J. Targeting Peroxisome Proliferator-Activated Receptor Delta (PPARδ): A Medicinal Chemistry Perspective. J Med Chem 2020; 63:10109-10134. [DOI: 10.1021/acs.jmedchem.9b01882] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- Tara Man Kadayat
- New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, Republic of Korea
| | - Aarajana Shrestha
- New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, Republic of Korea
- College of Pharmacy, Yeungnam University, Gyeongsan 38541, Republic of Korea
| | - Yong Hyun Jeon
- Laboratory Animal Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, Republic of Korea
- Leading-edge Research Center for Drug Discovery and Development for Diabetes and Metabolic Disease, Kyungpook National University Hospital, Daegu 41404, Republic of Korea
| | - Hongchan An
- New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, Republic of Korea
| | - Jina Kim
- New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, Republic of Korea
| | - Sung Jin Cho
- New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, Republic of Korea
- Leading-edge Research Center for Drug Discovery and Development for Diabetes and Metabolic Disease, Kyungpook National University Hospital, Daegu 41404, Republic of Korea
| | - Jungwook Chin
- New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, Republic of Korea
| |
Collapse
|
4
|
Shi Y, Zou Y, Shen Z, Xiong Y, Zhang W, Liu C, Chen S. Trace Elements, PPARs, and Metabolic Syndrome. Int J Mol Sci 2020; 21:E2612. [PMID: 32283758 PMCID: PMC7177711 DOI: 10.3390/ijms21072612] [Citation(s) in RCA: 56] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2020] [Revised: 04/06/2020] [Accepted: 04/07/2020] [Indexed: 12/13/2022] Open
Abstract
Metabolic syndrome (MetS) is a constellation of metabolic derangements, including central obesity, insulin resistance, hypertension, glucose intolerance, and dyslipidemia. The pathogenesis of MetS has been intensively studied, and now many factors are recognized to contribute to the development of MetS. Among these, trace elements influence the structure of proteins, enzymes, and complex carbohydrates, and thus an imbalance in trace elements is an independent risk factor for MetS. The molecular link between trace elements and metabolic homeostasis has been established, and peroxisome proliferator-activated receptors (PPARs) have appeared as key regulators bridging these two elements. This is because on one hand, PPARs are actively involved in various metabolic processes, such as abdominal adiposity and insulin sensitivity, and on the other hand, PPARs sensitively respond to changes in trace elements. For example, an iron overload attenuates hepatic mRNA expression of Ppar-α; zinc supplementation is considered to recover the DNA-binding activity of PPAR-α, which is impaired in steatotic mouse liver; selenium administration downregulates mRNA expression of Ppar-γ, thereby improving lipid metabolism and oxidative status in the liver of high-fat diet (HFD)-fed mice. More importantly, PPARs' expression and activity are under the control of the circadian clock and show a robust 24 h rhythmicity, which might be the reasons for the side effects and the clinical limitations of trace elements targeting PPARs. Taken together, understanding the casual relationships among trace elements, PPARs' actions, and the pathogenesis of MetS is of great importance. Further studies are required to explore the chronopharmacological effects of trace elements on the diurnal oscillation of PPARs and the consequent development of MetS.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Siyu Chen
- State Key Laboratory of Natural Medicines and School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, China
| |
Collapse
|
5
|
Oxidative umpolung selenocyanation of ketones and arenes: An efficient protocol to the synthesis of selenocyanates. Tetrahedron 2020. [DOI: 10.1016/j.tet.2020.130978] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
6
|
Lee SJ, Samala M, Woo SY, Hahn D, Kim D, Kadayat TM, Jung K, Kim J, Kim DS, Kwon S, Kim S, Kim KH, Nam SJ, Cho SJ, Chin J. Enantioselective Synthesis of a Novel Thiazoline Core as a Potent Peroxisome Proliferator-Activated Receptor δ Agonist. ACS OMEGA 2018; 3:1970-1976. [PMID: 30023820 PMCID: PMC6044852 DOI: 10.1021/acsomega.7b01689] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 11/01/2017] [Accepted: 01/29/2018] [Indexed: 06/08/2023]
Abstract
The convergent and enantioselective synthesis of a highly potent human peroxisome proliferator-activated receptor delta agonist is presented. More specifically, the thiazoline structure, which constitutes the biosynthetically distinctive core structure of pulicatin (a secondary metabolite of symbiotic bacteria), was synthesized from a commercially available and inexpensive chiral pool of l-threonine.
Collapse
Affiliation(s)
- Su-Jeong Lee
- New
Drug Development Center, Daegu-Gyeongbuk
Medical Innovation Foundation, Daegu 41061, Republic
of Korea
| | - Mallesham Samala
- College
of Pharmacy, Kangwon National University, Chuncheon, Gangwon-do 24341, Republic of Korea
| | - Seo Yeon Woo
- New
Drug Development Center, Daegu-Gyeongbuk
Medical Innovation Foundation, Daegu 41061, Republic
of Korea
| | - Dongyup Hahn
- School of Food Science and Biotechnology, and College of Pharmacy, Kyungpook National University, Daegu 41566, Republic
of Korea
| | - Dayoung Kim
- Department
of Chemistry and Nano Science, Global Top 5 Program, Ewha Womans University, Seoul 03760, Republic of Korea
| | - Tara Man Kadayat
- New
Drug Development Center, Daegu-Gyeongbuk
Medical Innovation Foundation, Daegu 41061, Republic
of Korea
| | - Kyungjin Jung
- New
Drug Development Center, Daegu-Gyeongbuk
Medical Innovation Foundation, Daegu 41061, Republic
of Korea
| | - Jina Kim
- New
Drug Development Center, Daegu-Gyeongbuk
Medical Innovation Foundation, Daegu 41061, Republic
of Korea
| | - Dong-Su Kim
- New
Drug Development Center, Daegu-Gyeongbuk
Medical Innovation Foundation, Daegu 41061, Republic
of Korea
| | - Sugyeong Kwon
- New
Drug Development Center, Daegu-Gyeongbuk
Medical Innovation Foundation, Daegu 41061, Republic
of Korea
| | - Shinae Kim
- New
Drug Development Center, Daegu-Gyeongbuk
Medical Innovation Foundation, Daegu 41061, Republic
of Korea
- School of Food Science and Biotechnology, and College of Pharmacy, Kyungpook National University, Daegu 41566, Republic
of Korea
| | - Kyung-Hee Kim
- New
Drug Development Center, Daegu-Gyeongbuk
Medical Innovation Foundation, Daegu 41061, Republic
of Korea
| | - Sang-Jip Nam
- Department
of Chemistry and Nano Science, Global Top 5 Program, Ewha Womans University, Seoul 03760, Republic of Korea
| | - Sung Jin Cho
- New
Drug Development Center, Daegu-Gyeongbuk
Medical Innovation Foundation, Daegu 41061, Republic
of Korea
| | - Jungwook Chin
- New
Drug Development Center, Daegu-Gyeongbuk
Medical Innovation Foundation, Daegu 41061, Republic
of Korea
| |
Collapse
|
7
|
Ramisetti SR, Pandey MK, Lee SY, Karelia D, Narayan S, Amin S, Sharma AK. Design and synthesis of novel thiobarbituric acid derivatives targeting both wild-type and BRAF-mutated melanoma cells. Eur J Med Chem 2017; 143:1919-1930. [PMID: 29133035 DOI: 10.1016/j.ejmech.2017.11.006] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2017] [Revised: 11/01/2017] [Accepted: 11/02/2017] [Indexed: 11/28/2022]
Abstract
A series of novel thio- and seleno-barbituric acid derivatives were synthesized by varying the substituents at N1 and N3 (ethyl, methyl, allyl, and phenyl), and C5 tethered with dienyl and trienyl moieties attached to substituents such as phenyl, 2-furanyl, 2-thiophenyl, 1-naphthyl, and 3-pyridyl. The cytotoxic potential of these derivatives was evaluated by using MTT assay against melanoma cell lines expressing either wild-type (CHL-1) or mutant (UACC 903) BRAF gene. Among all, 2b and 8b were identified as the most potent compounds. Both 2b and 8b inhibited viability of various melanoma cells and induced cell death as evidenced by Live and Dead assay. Western blot analysis showed that they induce PARP cleavage and inhibit anti-apoptotic Bcl-2, Bcl-xL and Survivin in a dose-dependent manner within 24 h of the treatment. Novel thiobarbituric acid analogs also inhibited viability of various other solid tumor cell lines, such as pancreatic, breast, and colon. Overall, 2b, 2d, and 8b emerged as the most effective compounds and make good leads for the development of future therapeutic agents.
Collapse
Affiliation(s)
- Srinivasa Rao Ramisetti
- Department of Pharmacology, Penn State Cancer Institute, CH72, Penn State College of Medicine, 500 University Drive, Hershey, PA 17033, USA
| | - Manoj K Pandey
- Department of Pharmacology, Penn State Cancer Institute, CH72, Penn State College of Medicine, 500 University Drive, Hershey, PA 17033, USA
| | - Sang Y Lee
- Department of Neurosurgery, Penn State Cancer Institute, CH72, Penn State College of Medicine, 500 University Drive, Hershey, PA 17033, USA
| | - Deepkamal Karelia
- Department of Pharmacology, Penn State Cancer Institute, CH72, Penn State College of Medicine, 500 University Drive, Hershey, PA 17033, USA
| | - Satya Narayan
- Department of Anatomy and Cell Biology, University of Florida, Gainesville, FL 32610, USA
| | - Shantu Amin
- Department of Pharmacology, Penn State Cancer Institute, CH72, Penn State College of Medicine, 500 University Drive, Hershey, PA 17033, USA
| | - Arun K Sharma
- Department of Pharmacology, Penn State Cancer Institute, CH72, Penn State College of Medicine, 500 University Drive, Hershey, PA 17033, USA.
| |
Collapse
|
8
|
Chalcogen containing heterocyclic scaffolds: New hybrids with antitumoral activity. Eur J Med Chem 2016; 123:407-418. [PMID: 27487570 DOI: 10.1016/j.ejmech.2016.07.042] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2016] [Revised: 06/21/2016] [Accepted: 07/19/2016] [Indexed: 12/14/2022]
Abstract
In this work, 27 novel hybrid derivatives containing diverse substituents with chalcogen atoms (selenium or sulfur) and several active heterocyclic scaffolds have been synthesized. Compounds were tested against two human cancer cells lines (MCF7 and PC-3) and a normal human mammary epithelial cell line (184B5) in order to determine their activity and selectivity against malignant cells. Ten compounds showed GI50 values below 10 μM in at least one of the cancer cell lines and six of them exhibited a selectivity index higher than 9. In general, selenium-containing compounds were more active than their corresponding sulfur analogs but we found some thiocyanate derivatives with comparable or higher activity and selectivity. Among the different substituents, the seleno- and thio-cyanate groups showed the most promising results. On the basis of their potent activity and high selectivity index, compounds 7e and 8f (containing a thiocyanate and a selenocyanate group, respectively) were selected for further biological evaluation. Both the compounds induced caspase-dependent cell death and cell cycle arrest in G2/M phase. In addition, these compounds do not violate any of the Lipinski's Rule of Five and thus possess good potential to become drugs, compound 7e being particularly promising.
Collapse
|
9
|
Wang J, Yang F, Zheng L, Ren G, Qi J, Wang Z, Zhao L. Novel selenium-containing acenaphtho[1,2-b]pyrrole derivatives: Synthesis and bioactivity. PHOSPHORUS SULFUR 2016. [DOI: 10.1080/10426507.2015.1072187] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- Jisong Wang
- Department of Oncology, Laiwu City People's Hospital, Shandong, P. R. China
| | - Fuli Yang
- Department of Oncology, Laiwu City People's Hospital, Shandong, P. R. China
| | - Liang Zheng
- Department of Respiration, Laiwu City People's Hospital, Shandong, P. R. China
| | - Gang Ren
- Department of Oncology, Laiwu City People's Hospital, Shandong, P. R. China
| | - Jiude Qi
- Department of Oncology, Laiwu City People's Hospital, Shandong, P. R. China
| | - Zhijun Wang
- Shandong Wego Pharmaceutical Co. Limited, Shandong, P. R. China
| | - Liwei Zhao
- Shandong Wego Pharmaceutical Co. Limited, Shandong, P. R. China
| |
Collapse
|
10
|
Kinarivala N, Suh JH, Botros M, Webb P, Trippier PC. Pharmacophore elucidation of phosphoiodyn A - Potent and selective peroxisome proliferator-activated receptor β/δ agonists with neuroprotective activity. Bioorg Med Chem Lett 2016; 26:1889-93. [PMID: 26988304 DOI: 10.1016/j.bmcl.2016.03.028] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2016] [Revised: 03/07/2016] [Accepted: 03/08/2016] [Indexed: 10/22/2022]
Abstract
We report the pharmacophore of the peroxisome proliferator-activated receptor δ (PPARδ) agonist natural product phosphoiodyn A is the phosphonate core. Synthesis of simplified phosphonate esters 13 and 15 provide structurally novel, highly selective and potent PPARδ agonists (EC50=78 and 112 nM, respectively). Further, both compounds demonstrate significant neuroprotective activity in an in vitro cellular model indicating that phosphonates may be an effective novel scaffold for the design of therapeutics for the treatment of neurodegenerative disorders.
Collapse
Affiliation(s)
- Nihar Kinarivala
- Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA
| | - Ji Ho Suh
- The Methodist Hospital Research Institute, Genomic Medicine Program, Houston, TX 77030, USA
| | - Mina Botros
- Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA
| | - Paul Webb
- The Methodist Hospital Research Institute, Genomic Medicine Program, Houston, TX 77030, USA
| | - Paul C Trippier
- Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA; Center for Chemical Biology, Department of Chemistry and Biochemistry, Texas Tech University, Lubbock, TX 79409, USA.
| |
Collapse
|
11
|
Lü J, Zhang J, Jiang C, Deng Y, Özten N, Bosland MC. Cancer chemoprevention research with selenium in the post-SELECT era: Promises and challenges. Nutr Cancer 2015; 68:1-17. [PMID: 26595411 PMCID: PMC4822195 DOI: 10.1080/01635581.2016.1105267] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
The negative efficacy outcomes of double-blinded, randomized, placebo-controlled Phase III human clinical trials with selenomethionine (SeMet) and SeMet-rich selenized-yeast (Se-yeast) for prostate cancer prevention and Se-yeast for prevention of nonsmall cell lung cancer (NSCLC) in North America lead to rejection of SeMet/Se-yeast for cancer prevention in Se-adequate populations. We identify 2 major lessons from the outcomes of these trials: 1) the antioxidant hypothesis was tested in wrong subjects or patient populations, and 2) the selection of Se agents was not supported by cell culture and preclinical animal efficacy data as is common in drug development. We propose that next-generation forms of Se (next-gen Se), such as methylselenol precursors, offer biologically appropriate approaches for cancer chemoprevention but these are faced with formidable challenges. Solid mechanism-based preclinical efficacy assessments and comprehensive safety studies with next-gen Se will be essential to revitalize the idea of cancer chemoprevention with Se in the post-SELECT era. We advocate smaller mechanism-driven Phase I/II trials with these next-gen Se to guide and justify future decisions for definitive Phase III chemoprevention efficacy trials.
Collapse
Affiliation(s)
- Junxuan Lü
- Department of Biomedical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center. 1300 S. Coulter St, Amarillo, TX79106 (JL, JZ, CJ)
| | - Jinhui Zhang
- Department of Biomedical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center. 1300 S. Coulter St, Amarillo, TX79106 (JL, JZ, CJ)
| | - Cheng Jiang
- Department of Biomedical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center. 1300 S. Coulter St, Amarillo, TX79106 (JL, JZ, CJ)
| | - Yibin Deng
- Hormel Institute, University of Minnesota, Austin, MN 55912 (YD)
| | - Nur Özten
- Department of Pathology, University of Illinois at Chicago (UIC), College of Medicine, Chicago, IL (NO, MCB)
- Department of Pharmaceutical Toxicology, Faculty of Pharmacy, Bezmiâlem Vakif University, Istanbul, Turkey (NO)
| | - Maarten C. Bosland
- Department of Pathology, University of Illinois at Chicago (UIC), College of Medicine, Chicago, IL (NO, MCB)
| |
Collapse
|
12
|
Navarrete-Vázquez G, Torres-Gómez H, Hidalgo-Figueroa S, Ramírez-Espinosa JJ, Estrada-Soto S, Medina-Franco JL, León-Rivera I, Alarcón-Aguilar FJ, Almanza-Pérez JC. Synthesis, in vitro and in silico studies of a PPARγ and GLUT-4 modulator with hypoglycemic effect. Bioorg Med Chem Lett 2014; 24:4575-4579. [DOI: 10.1016/j.bmcl.2014.07.068] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2014] [Revised: 07/22/2014] [Accepted: 07/24/2014] [Indexed: 10/25/2022]
|
13
|
Hidalgo-Figueroa S, Ramírez-Espinosa JJ, Estrada-Soto S, Almanza-Pérez JC, Román-Ramos R, Alarcón-Aguilar FJ, Hernández-Rosado JV, Moreno-Díaz H, Díaz-Coutiño D, Navarrete-Vázquez G. Discovery of Thiazolidine-2,4-Dione/Biphenylcarbonitrile Hybrid as Dual PPAR α/γ Modulator with Antidiabetic Effect:In vitro, In SilicoandIn VivoApproaches. Chem Biol Drug Des 2013; 81:474-83. [DOI: 10.1111/cbdd.12102] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2012] [Revised: 12/06/2012] [Accepted: 12/10/2012] [Indexed: 12/20/2022]
Affiliation(s)
- Sergio Hidalgo-Figueroa
- Facultad de Farmacia; Universidad Autónoma del Estado de Morelos; Av. Universidad 1001; Chamilpa; Cuernavaca Mor.; 62209; México
| | - Juan J. Ramírez-Espinosa
- Facultad de Farmacia; Universidad Autónoma del Estado de Morelos; Av. Universidad 1001; Chamilpa; Cuernavaca Mor.; 62209; México
| | - Samuel Estrada-Soto
- Facultad de Farmacia; Universidad Autónoma del Estado de Morelos; Av. Universidad 1001; Chamilpa; Cuernavaca Mor.; 62209; México
| | - Julio C. Almanza-Pérez
- Laboratorio de Farmacología; Depto. Ciencias de la Salud, D.C.B.S.; Universidad Autónoma Metropolitana-Iztapalapa; Apdo.-Postal 55-535; CP 09340; México; D.F.; México
| | - Rubén Román-Ramos
- Laboratorio de Farmacología; Depto. Ciencias de la Salud, D.C.B.S.; Universidad Autónoma Metropolitana-Iztapalapa; Apdo.-Postal 55-535; CP 09340; México; D.F.; México
| | - Francisco J. Alarcón-Aguilar
- Laboratorio de Farmacología; Depto. Ciencias de la Salud, D.C.B.S.; Universidad Autónoma Metropolitana-Iztapalapa; Apdo.-Postal 55-535; CP 09340; México; D.F.; México
| | - Jesús V. Hernández-Rosado
- Posgrado en Biología Experimental, D.C.B.S.; Universidad Autónoma Metropolitana-Iztapalapa; Apdo.-Postal 55-535; CP 09340; México; D.F.; México
| | - Hermenegilda Moreno-Díaz
- Universidad del Papaloapan, Campus Tuxtepec; Circuito Central 200, Col. Parque Industrial; 68301; Tuxtepec; Oaxaca; México
| | - Daniel Díaz-Coutiño
- Universidad del Papaloapan, Campus Tuxtepec; Circuito Central 200, Col. Parque Industrial; 68301; Tuxtepec; Oaxaca; México
| | - Gabriel Navarrete-Vázquez
- Facultad de Farmacia; Universidad Autónoma del Estado de Morelos; Av. Universidad 1001; Chamilpa; Cuernavaca Mor.; 62209; México
| |
Collapse
|
14
|
Abstract
Selenium is an essential trace element for humans and other animals that is required in very small amounts for proper growth and functioning. Several selenium compounds have shown promise as cancer chemopreventive and chemotherapeutic agents. However, the negative outcome of the SELECT trial to some extent dampened the enthusiasm of selenium-related drug development. A look at the selenium compounds, their diverse mechanism of action, bioavailability and efficacy based on chemical structure, however, suggests that failure of SELECT that used selenomethionine supplement to prevent prostate cancer was not a failure of selenium compounds as a whole. This is certainly true in regard to therapeutic applications of selenium compounds. This article puts these arguments in perspective, and based on the literature reports, especially several newly developed selenium compounds, emphasizes the importance of selenium in the development of chemopreventive and particularly chemotherapeutic drugs for cancer in near future.
Collapse
|
15
|
Selenium-containing naphthalimides as anticancer agents: Design, synthesis and bioactivity. Bioorg Med Chem 2012; 20:2558-63. [DOI: 10.1016/j.bmc.2012.02.049] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2011] [Revised: 02/21/2012] [Accepted: 02/22/2012] [Indexed: 12/11/2022]
|
16
|
Lipophilicity of acidic compounds: Impact of ion pair partitioning on drug design. Bioorg Med Chem Lett 2011; 21:3550-6. [DOI: 10.1016/j.bmcl.2011.04.133] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2011] [Revised: 04/27/2011] [Accepted: 04/27/2011] [Indexed: 11/23/2022]
|